Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

BACKGROUND: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011. METHODS: Eligible patients with refractory advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Anthoney, D Alan, Naik, Jay, MacPherson, Iain RJ, Crawford, Donna, Hartley, John M, Hartley, Janet A, Saito, Tomohisa, Abe, Masaichi, Jones, Keith, Miwa, Masanori, Twelves, Christopher, Evans, TRJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517777/
https://www.ncbi.nlm.nih.gov/pubmed/23170896
http://dx.doi.org/10.1186/1471-2407-12-536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517777/
https://www.ncbi.nlm.nih.gov/pubmed/23170896
http://dx.doi.org/10.1186/1471-2407-12-536

Ejemplares similares